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ABSTRACT
Objective To evaluate the implementation of a
multicomponent survivorship programme for men with
prostate cancer and their carers.
Design A single cohort study, guided by the RE-AIM
framework.
Setting Multiple health services in Australia.
Participants Men with prostate cancer and their carers,
and health professionals.
Intervention A 12-month telehealth programme that
provided centralised and coordinated decision and
information support, exercise and nutrition management,
specialised clinical support and practical support to men
and their carers.
Data collection Multiple sources of data including
participant-reported health outcomes and experience of
care, qualitative interviews, records of the programme
were collected at different time points.
Results Reach: Of 394 eligible men at various stages
of survivorship, 142 consented (36% consent rate) and
136 (96%) completed the programme. Adoption: All men
participated in general care coordination and more than
half participated in exercise and/or nutrition management
interventions. Participation in the specialised support
component (ie, psychosocial and sexual health support,
continence management) was low despite the high
level of need reported by men. Effectiveness: Overall,
the men reported improvements in their experience
of care. Implementation: Factors such as addressing
service gaps, provision of specialised services, care
coordination, adoption of needs-based and telehealth-
based approaches were identified as enablers to the
successful implementation of the programme. Issues such
as insufficient integration with existing services, lack of
resources and high caseload of the intervention team,
men’s reluctance to discuss needs and lack of confidence
with technology were barriers in implementing the
programme.
Conclusion Survivorship interventions are relevant
to men regardless of the stage of their disease and
treatments undertaken. It is possible to provide access to a
comprehensive model of survivorship care to promote the
health and quality of life for men with prostate cancer.

Strengths and limitations of this study
► This is one of the only studies that have evaluated

the implementation of multicomponent survivorship
interventions for men with prostate cancer and their
carers.
► Applying the RE-
AIM framework, this study has
assessed the Reach, Effectiveness, Adoption and
Implementation of the intervention.
► This study is limited by the absence of a comparison group to determine efficacy. Nonetheless, the
multiple sources of data collected provide support
for continuing to build on the principles and components of such model of care.

Trial registration number This study was registered with
the Australian and New Zealand Clinical Trials Registry
(ACTRN12617000174381).

INTRODUCTION
Ongoing advances in prostate cancer diagnosis and treatment, combined with population ageing, have resulted in continued
growth in the number of prostate cancer
survivors across many high-
resource countries.1–3 Many survivors experience a range
of disease and treatment related symptoms
that negatively impact physical, psychosocial
and social functioning. Frequently reported
short-
term and long-
term unmet needs
relate to sexual health and relationships,
urinary incontinence, informational, physical and psychological needs.4–6 However,
the evidence base for supportive care interventions to address these needs is limited.
One Cochrane review7 of the effectiveness
of psychosocial interventions for men with
prostate cancer has highlighted the potential for such care, concluding that men who
received psychosocial intervention had a
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small but short-
term improvement in their physical
and cancer-related quality of life and prostate cancer
knowledge.
In response to gaps in survivorship care for men with
prostate cancer, Movember (a global charity organisation) developed a global programme (known as
TrueNTH) seeking to design, implement and evaluate
survivorship interventions across a number of countries.
In Australia, the Movember team designed an integrated
multicomponent survivorship programme for men with
prostate cancer and their carers.8 This care model was
focused on addressing gaps in existing programmes that
indicated that most to date had focused on single prostate cancer symptoms or side effects or a single intervention approach. It was based on recommendations from
cancer survivorship models9 10 that highlight the benefits
of integrated approaches and risk stratification to enable
interventions to be delivered according to need, thereby
ensuring both person centred care as well as efficient use
of scarce health resources. The importance of engaging
primary care services for follow-up survivorship care after
the acute treatment phase is also recommended to ensure
long-term adverse effects are addressed.
The resulting programme involved core components of care coordination, information provision, decision support, self-
management, exercise and nutrition
management, as well as referral to specialised services
(continence advice, sexual health counselling and psychological support) where required. The programme was
successfully evaluated in a feasibility study11 involving 51
men and 13 carers, which confirmed that it was accepted
by men, largely implemented as per protocol, and that
the proposed evaluation procedures were acceptable and
feasible for men across all stages of disease. In this paper,
we report findings from a larger scale study designed to
evaluate the implementation of the programme across
multiple services throughout Australia. Specifically, this
study uses the RE-AIM framework12 to assess the reach,
effectiveness, adoption, implementation and maintenance of the programme.
The objectives of the study were to: (1) describe the
nature and scope of the programme and how it was
implemented in various healthcare contexts in terms of
the reach of the programme to different populations,
adoption of intervention components and consistency
and adaptations made to the interventions; (2) evaluate
the impact of the programme on men’s prostate health
symptoms, psychological distress, experience of care and
health behaviour; (3) identify contextual factors influencing the implementation of the programme in terms of
health system and health professional issues, patient and
carer factors and sustainability of the programme and (4)
conduct a comprehensive cost analysis of the programme.
In this paper, we report findings relating to the first
three objectives only. Findings relating to cost analysis
and the broader economic evaluation incorporating the
quality-of life instrument (EQ-5D-5L) will be reported
elsewhere.
2

MATERIALS AND METHODS
Study design
This study involved a single group design with prospective assessment at different time points over a 12-month
period, whereby all consented men and their partner/
carer were enrolled in the programme. A mix of quantitative and qualitative data were collected from a range of
sources to address the elements of the RE-AIM framework.
Setting and sample
Four public hospitals and five private health services in
Victoria, Queensland, Northern Territory and South
Australia participated in the programme. Men who had
been diagnosed with prostate cancer were eligible if they
were receiving services from any of the participating
sites. Men were excluded from the study if they were too
unwell (as determined by their treating specialist), or
had physical, psychological or cognitive difficulties that
would prevent them from participating in the study. The
treating specialists (eg, urologist, radiation or medical
oncologist) or nominated clinical contact at sites identified potential participants and referred them to the
research team at the coordinating university (QUT) for
consent after gaining permission from the man for the
referral. Written consent was sought for participation in
the study, with a separate optional consent for access to
their individual healthcare data (to be reported separately) from the Department of Human Services for the
purpose of economic evaluation.
The referring specialists were informed about the
man’s participation in the study. All consented men were
also asked to nominate a general practitioner (GP) to be
part of his care team. In addition, they were asked if they
wished to nominate a partner/carer. Written consents
were obtained from the nominated partner/carer.
Key clinicians of the treating team, TrueNTH service
providers and Movember representatives were also invited
to take part in the evaluation of the programme. Written
consents were obtained from these staff.
The Australian TrueNTH programme
The programme delivered a multicomponent integrated
model of care to men with prostate cancer that is illustrated in figure 1.
Features of intervention delivery
The key features of the model included care that was coordinated by a single point of contact who was a registered
nurse (care coordinator) with experience in urology
and/or prostate cancer nursing. Prior to site initiation,
the Coordinator engaged with each site and conducted
a scoping exercise to identify key support services and
resources provided for men with prostate cancer and
their carers by local health and community service
providers. To ensure a consistent standard of delivery for
the components of the intervention, Movember engaged
expert service providers with experience in prostate
cancer to provide centralised services that complemented
Yates P, et al. BMJ Open 2022;12:e049802. doi:10.1136/bmjopen-2021-049802
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a 3 monthly basis or when new symptoms emerged. An
alert was sent to the Coordinator and GP when patient
assessments were completed. If the man did not want to
use the tool to communicate with the care team or access
information, hard copies of information and the care
plan were provided.

Figure 1

TrueNTH care model.

local services where relevant. All centralised services were
delivered remotely using telephone, mobile phone or
video conference.
Men were allocated, based on their stage of prostate
cancer and treatment received at enrolment, to one of
five care pathways (as shown in table 1) developed for the
intervention based on findings from the feasibility study.
An online care management tool (cdmNet (It is now
called Inca)) was used to manage and support care planning, delivery and review of the services by all members
of the care team throughout the care continuum. Men
were provided with this tool, which enabled them to
access their individualised care plan and undertake
ongoing self-monitoring of their symptoms and needs on

Intervention components
Information, education and decision support
At enrolment, the Coordinator remotely conducted a
comprehensive assessment with each man to assess his
prostate cancer-specific symptoms, as well as their general
and psychological health, nutrition status and supportive
care needs. Men were provided with an evidence-based
education package and decision support material relevant
to their stage of disease and treatment. The outcome of
the assessment was communicated to the man’s treating
specialist/team and GP via email or mail. This information provided the basis for development of a care plan
and referrals to appropriate specialist support services
according to the men’s health needs and preferences,
preference of treating specialist/team and the availability
of local resources. Moreover, the Coordinator liaised with
the man’s GP to facilitate additional assessments for risks
of conditions or management of comorbidities, such as
osteoporosis, cardiovascular disease, obesity and diabetes.
Based on the assessment, the GP liaised with the treating
team to facilitate the management of any identified risk
factors and conditions.
All men were also provided with information about
peer support programmes and referred to relevant

Table 1 Definition of TrueNTH care pathway and data collection points
Preintervention

After enrolment in the intervention

Definition

T0

T1

T2

T3

T4

Men with localised prostate
cancer who were undergoing
active surveillance
Men with localised prostate
cancer who were undergoing
radiation therapy

At enrolment

3 months

5 months

8 months

12 months

5 months

8 months

12 months

Surgery

Men with localised prostate
cancer who were undergoing
surgery or completed surgery no
more than 3 months

At enrolment

3 months

6 months

9 months

12 months

Treatment
completed

Men with localised prostate
cancer who had completed
primary treatment
Men with advanced prostate
cancer who had metastatic
disease or biochemical
recurrence progressing before
or after salvage treatment, or
who were ineligible for salvage
treatment

At enrolment

3 months

6 months

9 months

12 months

At enrolment

3 months

6 months

Allocated
subgroups
Active
surveillance
Radiation
therapy

Advanced
prostate cancer

At enrolment

/

/

12 months

/ indicates no data collection occurred at the time.
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support services to address their needs relating to transport, accommodation, finance, legal, employment and
respite services for carers, as required.
Exercise and nutrition management
All men were referred to a centralised accredited exercise physiologist (AEP; Exercise and Sport Science
Australia) and received an evidence-
based exercise
prescription regardless of their stage of disease, or their
past, current, or future treatments, financial capacity
or geographical location. This prescription was tailored
to each man to address the specific issues causing the
greatest concern, or to prepare for future treatments, or
to address post-treatment issues. The service was delivered remotely by one service provider through multiple
modes, including phone or online teleconferences, DVD,
online or paper materials, with referral to local exercise
physiology services depending on available resources in
their geographical location. All men were also referred
to dietetic services either locally or through a centralised
service using accredited practising dietitians (APD;
Dietitians Australia). Men underwent a comprehensive
nutritional assessment with the dietitian and received
an individualised nutrition prescription tailored to their
stage of disease, treatment plan, treatment-related side
effects, gastrointestinal tolerance/allergies, financial
capacity and geographical location. The dietetic intervention was designed to improve diet quality and reduce
weight gain and other prominent side effects of prostate
cancer treatment. For men who were malnourished, or
undergoing chemotherapy or radiotherapy, standardised
evidence-based guidelines were implemented to reduce
nutritional impact, symptoms of treatment, maintain oral
intake and reduce wasting of muscle mass and total body
mass.13

support as appropriate, which included provision of
required information, referrals to services for emotional
and general well-being concerns, as well as intimacy and
relationship counselling.
Data collection and measurements
Reach, adoption and implementation of the intervention
The research team at QUT maintained administrative
records of referrals, eligibility screening, reasons for
declining participation and the retention rates. Participant demographics were collected. The referring specialists provided clinical information of consented men at
enrolment, including cancer stage, grade, date of diagnosis, treatment received, comorbidities, prostate-specific
antigen level or other relevant test results (eg, CT/MRI
scans, X-rays). Information on intervention delivery and
attendance was documented by the intervention team
and captured by cdmNet. In addition, individual telephone interviews were conducted with selected men and
carers (by their care pathway, residence area, source of
referral) after 6 months following enrolment in the intervention to explore their experiences of prostate cancer
and care, ongoing unmet needs, and experiences with
the programme. Interviews were also conducted with
consented clinicians, TrueNTH service providers and
Movember representatives towards the end of the study
to provide insights into factors influencing the implementation of the intervention. Furthermore, an audit of progress notes and assessment records recorded on cdmNet
using a structured checklist was undertaken by a research
assistant not involved in delivery of the intervention. The
purpose of the audit was to objectively evaluate adherence and compliance to the study protocol in relation
to referral to centralised exercise and nutrition management services.
Effectiveness of the intervention
Depending on the allocated care pathway at enrolment,
up to five surveys (as shown in table 1) were collected
from the men and carers via post or online. Each survey
consisted of two questionnaires: the health outcome questionnaire and the health service utilisation questionnaire
(the economic evaluation will be reported separately).
The following health outcomes were assessed to explore
the changes over the intervention period using validated
instruments:

Specialised services
The Coordinator referred men to various specialised clinical supports at any point during the intervention. These
services were delivered remotely by a specialist service
engaged for the purposes of this project, which included
sexual health support, providing a range of sexual rehabilitation interventions in relation to physical functioning
and erectile rehabilitation, psychosexual, intimacy and
relationship functioning according to individual needs
and risk factors. Psychological support services were
also available. Men with mild anxiety or depression were
referred to an online self-management programme developed by the service providers, while those identified with
moderate or high anxiety and/or depression or other
mental health concerns were referred to a psychiatrist or
psychologist with expertise in prostate cancer, or cancer
in general. Men could also be referred to continence
management services if required.

Prostate cancer-specific quality of life
The Expanded Prostate Cancer Index short form (EPIC-
26)14 was used to measure prostate cancer-
specific
symptoms in relation to urinary incontinence, urinary
irritation/obstruction, bowel, sexual and hormonal
domains on 4-point or 5-point Likert scales, which was
transformed to 0–100 scores. Higher scores represent less
severe symptoms and better health-related quality of life.

Partner and carer support
Partners and carers were encouraged to participate in
the programme. The Coordinator provided them with

Psychological well-being
The General Health Questionnaire (GHQ-
12)15 16 was
used to assess psychological distress of men. The GHQ-12
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score ranges from 0 to 12 using the 0-
0-
1-
1 scoring
method; a higher score indicates a greater severity of
psychological distress.
General health behaviours
The original version of the Godin Leisure-Time Exercise
Questionnaire17 was used to evaluate health behavioural
change of the men. The total weekly leisure-time physical
activity score (Leisure Score Index (LSI)) was computed
and a higher score indicates a higher level of leisure-time
physical activity.
Experience of care
The National Cancer Control Indicators-
Patient Experience Indicator (NCCI-PEx 1–8) is an 8-item questionnaire developed by Cancer Australia (unpublished work,
2017). The questions incorporate the Cancer Australia
NCCI patient experience prioritised indicators and
measures from the diagnosis and treatment domains of
the framework. These prioritised indicators and measures
are based on the Cancer Patient Experience Survey developed by the National Health Service in England, modified for use in the Australian context.
Data analysis
Reach, adoption and implementation of the intervention
Descriptive statistics were used to summarise data relating
to recruitment, retention, utilisation of and compliance
with intervention components, and the demographic
and clinical characteristics of the men. For interview
data, thematic analysis was performed by two researchers
(RCo, W-HL) to identify the key perspectives of participants. This involved familiarising with the data, generating initial codes, searching for themes, reviewing
themes, defining and naming themes, and summarising
the findings. The third member of the research team
(PY) checked the themes identified.
Effectiveness of the intervention
All subgroups completed the outcomes questionnaires
at enrolment, 6 months and 12 months following enrolment. Therefore, data collected on these three time
points were used in the analyses. Scales and subscales were
constructed for each instrument following instrument
developer’s instructions. For each scale, if an individual
respondent had half or more of the total items missing
on any of the following scales, responses from the respondent were excluded from analyses related to that scale.
The study was not designed as a comparative effectiveness study, and as such no comparison group was
included. Instead, we explored trends that might be of
note to implementation of the intervention by comparing
changes over time at three points on men’s health
outcomes. For all measures, data were analysed as a whole
group. Subgroup analyses were also conducted according
to the care pathway. To compare changes over time within
a group/subgroup, one-way repeated-measures analysis
of variance’s were used if the outcome variables were
continuous. Non-parametric tests (ie, Cochran’s Q test)
Yates P, et al. BMJ Open 2022;12:e049802. doi:10.1136/bmjopen-2021-049802

were performed if the outcome variables were categorical. All analyses were performed using SPSS for Windows
(V.25.0). An alpha level of p≤0.05 was considered statistically significant. Additionally, minimally important difference (MID) values were used to determine if changes
in each domain of the EPIC measure were likely to be
clinically relevant. The suggested MID for each domain
of EPIC-
26 were 6–9 points for urinary incontinence,
5–7 points for urinary obstruction/irritation, 4–6 points
for bowel, 10–12 points for sexual, and 4–6 points for
hormonal symptoms.18
Patient and public involvement
Patient representatives were consulted and involved in
the development of the Australian TrueNTH programme.
They were not involved in the evaluation study design,
or analysis and interpretation of data, or writing of this
manuscript.

RESULTS
Reach of the intervention
The flow of participants through different phases of the
study is presented in figure 2. A total of 142 men and 59
carers participated in the study, representing a consent
rate of 36%. The intervention reached men across the
five care pathways, with the largest groups being men
who had completed treatment (41%), followed by men
with advanced disease (24%). During the study, five men
and three carers withdrew from the study. The main
reasons for withdrawal included feeling no need for
further services and support (n=3), deteriorating health
(n=1), and privacy concerns (n=1). One man died from
prostate cancer and one carer died due to unrelated
circumstances.
Of the 142 consented men, 127 (89%) returned a
completed baseline (T0) health outcome questionnaire,
and 99 (70%) and 92 (65%) returned follow-up questionnaires at 6 months (T2) and 12 months (T4) following
enrolment, respectively. A total of 80 men (56%) returned
questionnaires at all three time points.
Demographic and clinical characteristics of the men
at enrolment are summarised in table 2. Around 40%
(n=56) resided in major cities, 25% (n=36) lived in inner
regional areas and 35% (n=50) resided in rural/remote
areas. About 45% (n=61) of the men were working full
time/part time and 42% (n=57) were retired. Compared
with men who returned the questionnaire at 12 months,
those who did not were significantly younger (mean age
67 vs 64 years old, p=0.04), but not significantly different
in terms of other demographic and clinical characteristics.
Adoption of the intervention components
The uptake of the TrueNTH services by the men during
the study is summarised in table 3. All men received an
initial consultation with a TrueNTH care coordinator at
enrolment. A central component of the intervention was
the exercise and nutrition management services. The
5
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Figure 2

Flow diagram of recruitment and participation.

audit showed that 57% (n=81) of the men were referred
to both services, and 10% (n=14) were referred to one
of these services following the initial consultation. About
10% (n=15) of the men who were under the care of a
local care coordinator were referred back to the care
coordinator, as per protocol. Another 22% (n=31) were
referred to neither of the services and an explanation was
recorded relating to the man’s preferences and needs in
14 cases; but no explanation was provided in 17 cases. One
man decided to withdraw from the study at the consultation as he felt he did not need any support from the
programme. As a result, a total of 66 men participated in
both nutrition and exercise interventions, 14 participated
in the nutrition intervention only, and 23 participated in
the exercise intervention only. A total of 39 participated
in neither of these interventions. The main reason to
decline participation in the exercise and nutrition interventions was lack of interest. Of the 89 men who participated in the exercise programme, 47 were provided by
local services. However, only 5 of 80 men received nutrition interventions from local services. The proportion of
men who participated in TrueNTH nutrition, exercise,
psychosocial, continence and sexual health support did
not differ by the care pathway (see online supplemental
appendix 1).
Effectiveness of the intervention
Prostate cancer-specific quality of life
Mean scores and changes of men’s prostate cancer-
specific quality of life over the study period according to
the care pathway are summarised in table 4. Overall, men
consistently reported that the most severe bother was
related to sexual function (with the lowest mean score),
month
followed by urinary incontinence over the 12-
period. Given the absence of a comparison group our
analysis is not intended to determine efficacy but rather
to explore trends that may be of note to implementation
6

of the intervention. It was observed that men in the treatment completed subgroup experienced statistically significant improvement in the hormonal domain over the
study period.
The positive changes in the mean EPIC-26 hormonal
and urinary incontinence scores met the threshold for
MID in the treatment completed subgroup. Men in the
surgery subgroup also reported positive and clinically
relevant changes in the urinary incontinence and obstructive domains.
Psychological well-being and general health behaviour
Changes in psychological distress and total weekly leisure-
time activity levels of the men according to the care
pathway are presented in online supplemental appendix
2. Although we saw some evidence of reduced distress
level and improved LSI score in men as a whole group,
the changes were not statistically significant. Only men
in the treatment completed subgroup had significantly
improved in the LSI.
Experience of care
The proportion of men reporting satisfactory experience
of the healthcare system during prostate cancer diagnosis and treatment is presented in online supplemental
appendix 3. Overall, more men reported satisfactory
experiences of the healthcare system for seven of eight
statements at 12 months following enrolment in the intervention. However, only one improvement reached statistical significance, which was the proportion of men who
were offered a written assessment and care plan.
Implementation of the intervention
A total of 18 men and five carers, 6 clinicians, 13 TrueNTH
service providers and two Movember representatives
participated in the interviews. A range of health system,
intervention, healthcare provider and patient factors
Yates P, et al. BMJ Open 2022;12:e049802. doi:10.1136/bmjopen-2021-049802
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Table 2 Demographic and clinical characteristics of men (n=142) at enrolment
TrueNTH care pathway

Clinical characteristics
Age in years, mean (SD)
Age groups, n (%)

All men
(n=142)

Active
surveillance
(n=16)

Radiation
(n=6)

Surgery
(n=28)

Treatment
completed
(n=58)

Advanced
disease
(n=34)

65.8 (8.6)

61.9 (10.2)

69.8 (4.0)

61.9 (7.8)

66.9 (8.8)

68.3 (7.2)

 <41

1 (1)

1 (6)

0 (0)

0 (0)

0 (0)

0 (0)

 41–50

4 (3)

0 (0)

0 (0)

2 (7)

2 (3)

0 (0)

 51–60

29 (20)

6 (38)

0 (0)

9 (32)

8 (14)

6 (18)

 61–70

65 (46)

6 (38)

3 (50)

12 (43)

30 (52)

14 (41)

 71–80

34 (24)

2 (12)

3 (50)

5 (18)

12 (21)

12 (35)

9 (6)

1 (6)

0 (0)

0 (0)

6 (10)

2 (6)

 80+
Age at diagnosis, mean (SD)

62.6 (8.8)

59.2 (10.2)

69.5 (3.9)

61.1 (7.4)

62.8 (9.6)

63.8 (7.8)

Time since diagnosis (months),
median (range)

19 (1–196)

22 (1–123)

4 (3–5)

4 (1–88)

32 (7–196)

37 (1–175)

Time since diagnosis (months), n (%)
 <3

14 (10)

4 (25)

0 (0)

 3–6

27 (19)

3 (19)

6 (100)

9 (32)

0 (0)

1 (3)

14 (50)

0 (0)

4 (12)

 7–12

16 (11)

1 (6)

 13–24

21 (15)

0 (0)

0 (0)

1 (4)

10 (17)

4 (12)

0 (0)

2 (7)

14 (24)

5 (15)

 25–36

13 (9)

2 (12)

0 (0)

0 (0)

8 (14)

3 (9)

 >36

51 (36)

6 (38)

0 (0)

2 (7)

26 (45)

17 (50)

Stage of prostate cancer at enrolment, n (%)
 Localised

83 (59)

16 (100)

4 (67)

21 (75)

42 (72)

0 (0)

 Locally advanced

36 (25)

0 (0)

2 (33)

7 (25)

16 (28)

11* (32)

 Distant metastases

23 (16)

0 (0)

0 (0)

0 (0.0)

0 (0.0)

24 (17)

16 (100)

0 (0)

3 (11)

5 (9)

23 (68)

Treatment received, n (%)
 Active surveillance

0 (0)

 Surgery

85 (60)

N/A

0 (0)

28 (100)

40 (69)

17 (50)

 Hormone therapy

56 (39)

N/A

5 (83)

1 (4)

19 (33)

31 (91)

 Radiation therapy
 Chemotherapy

47 (33)
12 (9)

N/A
N/A

6 (100)
0 (0)

0 (0)
0 (0)

24 (41)
0 (0)

17 (50)
12 (35)

*With biochemical recurrence.
N/A, not applicable; SD, Standard deviation.

were identified as enablers and barriers to the successful
implementation of the intervention. These factors with
associated exemplar interview extracts are included in
tables 5 and 6.

DISCUSSION
This is one of the only studies that have evaluated the
implementation of multicomponent survivorship interventions for men with prostate cancer and their carers.
The study questions were focused on implementation of
the intervention and as such provides important insights
into factors to be considered in implementing such
approaches in this and other settings.
Yates P, et al. BMJ Open 2022;12:e049802. doi:10.1136/bmjopen-2021-049802

Overall, our findings were that while rates of enrolment in the study (36%) were lower than anticipated,
the intervention reached men at various stages of disease
living across metropolitan, rural and remote areas. Men
across all five care pathways participated in the intervention, with the largest group of participants being men
who had completed treatment (41%), followed by men
with advanced disease (24%). Over 60% of men were
diagnosed more than 12 months before enrolment highlighting the importance of longer-term support for men
with prostate cancer. Attrition from the programme was
low, with 96% of participants completing 12 months of
the programme.
7
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Table 3 Utilisation of the TrueNTH services over 12 months (total number of men=142)
No of episodes

TrueNTH services
Care coordination (initial
consultation)
Care coordination (follow-up)

No of
participants
(%)
Total

Phone

Teleconference

142 (100)

142

142

0

0

137 (97)

750

600

7

Email

No of
episodes per
participant
Median
(range)

Length of
episodes per
participant
median (range)
(in minutes)

1 (1–1)

60 (10–130)

143

5 (0–17)

145 (10–630)

Nutrition support

80 (56)

203

178

8

17

2 (1–8)

70 (5–275)

Exercise prescription

89 (63)

356

280

1

75

2 (1–17)

35 (2–184)

Psychosocial support

15 (11)

77

75

1

1

3 (1–21)

95 (15–505)

Sexual health
Continence support

10 (7)
9 (6)

28
22

22
22

0
0

6
0

2 (1–6)
2 (1–5)

145 (60–270)
45 (7–70)

The main reasons for declining participation in this
trial were no need for/no interest in support (37%) and
extra burden/being busy/away (28%). The low rate of
consent requires that we recognise the competing priorities of men and existing stressors when recruiting them
to such interventions. This may require introducing
components of the intervention at different time points
and in flexible ways to accommodate men’s readiness to
participate in various aspects of the intervention as well
as health literacy. Providing more information to men
about the importance of managing late effects of prostate
cancer and its treatment should be a priority.
Compared with population norms,19 the participants in
this study were slightly younger at diagnosis. However, the
wide age distribution of participants in this study confirms
that supportive care interventions can be tailored to
address age-related needs and concerns. Subgroup analyses conducted based on predefined care pathways highlighted the heterogeneity in patient characteristics and
severity of bother associated with various care needs. Our
evaluation is that programmes such as TrueNTH have
great potential as they allow for tailoring of services to
meet the specific needs of a diverse group of men living
with prostate cancer. Keys to the success of this approach
include comprehensive needs assessments, individualised
care planning and care coordination delivered by healthcare professionals with specialised knowledge of prostate
cancer.
Once enrolled in the study, uptake of general care coordination, exercise and nutrition management components of the intervention was high, and attrition was low.
However, participation in various other components of
the programme varied with only 11% receiving specialised psychosocial support, 7% sexual health support, and
6% continence management support, despite the high
level of need recorded in the quality of life assessments
of men in this study. The low uptake of these specialised
services could be explained by a range of factors. First,
low uptake may be due to the reluctance of care coordinators to refer patients to such services. That is, the local
8

care coordinators were experienced nurses who may have
felt they were able to meet these needs. Low uptake might
also reflect reluctance on the part of participants to seek
help for related concerns. One global general population
study20 reported that less than 20% of men experiencing
erectile difficulties sought help from a health professional.
Men believed that the problem was not serious, and they
were not bothered by the problem. Many men were also
not aware of available treatments. Additionally, the actual
rate of uptake of such services in this study may have been
under-reported, as the service utilisation data collected
were limited to the services provided by TrueNTH.
Variation in uptake of intervention components may
also reflect variability in Care Coordinator approaches
to implementation. Analysis of audit data relating to
decisions about referral to exercise and nutrition interventions revealed that in the majority of cases, care
coordinators applied the protocol consistently and
where referrals were not made a sound explanation was
provided relating to the individual man’s preferences and
needs. However, there were some cases where the reasons
for deviation from the protocol were not explained. This
lack of explanation could reflect limitations in record
keeping. It could also reflect some unexplained variation
in how individual care coordinators deliver their care.
The single group pre–post evaluation design used for
this study means that it is not possible to definitively
conclude that the TrueNTH programme led to statistically significant improvements in outcomes for men.
Nonetheless, the multiple sources of data collected as
part of this evaluation provide support for continuing to
build on the principles and components of the TrueNTH
model. Overall, men reported some improvements in
their experience of care. Men were also more likely to
engage in exercise-based interventions. These changes
in patient reported outcome measures over time provide
some evidence that the programme has the potential to
deliver important benefits for men.
The design of this study based on the RE-AIM framework12 also identified some important enablers and
Yates P, et al. BMJ Open 2022;12:e049802. doi:10.1136/bmjopen-2021-049802
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42
37

T2

T4
40

51

T0

Treatment completed
(n=58)

36
32

14

Change over time

Change T2–T0

15

Change T4–T0

Change T4–T0
Change over time

17

16

T4

Change T2–T0

18

T2

2
24

T0

Change over time

Surgery (n=28)

3

2

T4
2

3

T2

Change T4–T0

4

T0

Change T2–T0

Radiation (n=6)

11

13

T4
13

13

T2

Change over time

16

Active surveillance
(n=16)

Change T4–T0

78

T0

Change over time

13

87

Change T4–T0

Change T2–T0

94

92

T4

Change T2–T0

124
99

T0
T2

All men (n=142)

n

Time point

37
33
29

7.4*

34

39

48

9.0*
P=0.11

73.5 (27.6)

71.3 (27.8)

64.0 (34.3)

13

15

9.7*
P=0.32

16

16

17

24

2

2

3

2

3

4

10

12

12

13

13

15

71

81

87

88

118
94

n

0.8
P=0.24

5.1*

86.9 (16.6)

87.3 (15.3)

85.0 (18.6)

P=0.08

8.6*

7.4*

92.4 (8.3)

87.1 (15.5)

83.6 (16.8)

P=0.59

0.0

−6.3*

90.6 (4.4)

77.1 (15.7)

82.8 (10.7)

P=0.25

2.1

4.2

91.8 (10.0)

93.3 (10.0)

91.3 (11.0)

P=0.10

2.4

5.1*

85.0 (18.9)

82.8 (20.6)
84.5 (17.6)

Mean (SD)

Urinary obstructive

6.2*

75.9 (24.7)

66.0 (29.7)

59.3 (38.7)

P=0.50

0.0

−7.6*

100.0 (0.0)

92.4 (7.3)

95.2 (9.7)

P=0.74

3.0

3.0

88.2 (17.8)

89.6 (15.2)

87.5 (16.5)

P=0.18

4.4

4.8

74.8 (27.0)

69.9 (32.3)
73.4 (27.0)

Mean (SD)

Urinary incontinence

Domain

Prostate cancer-specific quality of life of men (n=142) by care pathway

Group

Table 4

31
28

35

33

39

46

13

15

16

16

17

24

2

2

3

2

3

4

10

12

13

12

13

16

68

76

86

85

114
95

n

Bowel

1.6
P=0.73

3.8

91.5 (15.8)

91.6 (13.2)

89.6 (17.0)

P=0.34

3.1

3.1

95.8 (7.0)

94.4 (7.8)

92.9 (10.2)

P=0.49

−6.3*

−12.5*

93.8 (2.9)

86.1 (20.6)

99.0 (2.1)

P=0.49

2.8

0.6

97.9 (4.9)

95.8 (11.8)

96.1 (9.6)

P=0.68

1.3

1.5

92.2 (15.4)

90.5 (14.4)
90.1 (15.7)

Mean (SD)

37
33

41

37

42

52

13

15

15

16

17

23

2

2

3

2

3

4

11

13

13

13

13

16

78

88

92

92

123
97

n

Sexual

8.3
P=0.09

5.5

23.9 (24.1)

23.1 (21.3)

19.7 (22.2)

P=0.13

−11.3*

−9.2

24.5 (24.4)

24.5 (21.6)

33.8 (31.0)

P=0.54

−3.9

−26.2*

18.3 (2.4)

12.2 (21.1)

33.0 (31.2)

P=0.32

−7.7

−8.2

54.6 (35.5)

57.5 (35.3)

66.0 (24.4)

P=0.42

−1.1

−2.0

25.1 (26.3)

28.0 (28.2)
25.0 (25.5)

Mean (SD)

34
31

39

34

40

51

13

15

16

16

17

24

1

1

2

3

3

3

10

12

13

12

13

16

73

82

91

87

123
96

n

Continued

6.9*
P=0.01

5.5*

82.2 (16.6)

80.6 (18.9)

77.7 (17.8)

P=0.41

2.7

1.0

84.7 (18.1)

81.3 (16.0)

84.7 (16.3)

/

40.0*

12.5*

76.7 (25.9)

75.8 (11.8)

75.0 (17.3)

P=0.66

2.9

1.9

91.7 (13.4)

91.2 (14.3)

90.9 (13.6)

P=0.12

3.7

2.1

78.2 (22.0)

76.8 (20.5)
76.9 (21.5)

Mean (SD)

Hormonal
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−2.3
P=0.15
−6.0
P=0.25
T0=at enrolment, T2=6 months following enrolment, T4=12 months following enrolment.
/indicates no data.
Scores range from 0 to 100; higher scores represent better quality of life in the domain.
Bold value means the difference in mean scores between two time points reaches the suggested MID
*Difference in mean scores between two time points reaches the suggested MID.
MID, minimally important difference.

21
19
Change T4–T0
Change over time

−6.5*
P=0.22

15
17

0.7
P=0.60

16
15

−1.0
P=0.74

21
19

20
18

−4.1*

60.8 (25.7)

−4.4

21

12.1 (9.7)

20
19

−1.4

22
72.6 (25.5)

5.3*
19

23
67.0 (30.0)

1.5
21

24
T4

Change T2–T0

20

87.4 (21.5)

23

59.3 (24.0)

61.1 (22.5)
29

23
11.7 (10.2)
22
81.7 (21.9)

16.4 (16.3)
28
84.8 (14.7)

23

24
73.6 (28.7)

73.3 (21.9)
22

27

23
T2

71.2 (27.0)

29
T0

Advanced disease
(n=34)

75.9 (25.1)

Mean (SD)
n
n
Time point
Group

Mean (SD)

n

Mean (SD)

n

Mean (SD)

n

Mean (SD)

Hormonal
Sexual
Bowel
Urinary obstructive
Urinary incontinence

Domain
Continued
Table 4
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barriers to implementation of the programme in the
participating settings. These factors were at the health
system, intervention, healthcare professional and patient
level, and provide important information to guide the
successful development and implementation of complex
interventions. In particular, the enablers and barriers to
use of the technology-based features of the intervention
can inform future developments in digital innovations in
healthcare, as the demands increase for such advances in
the healthcare system. The importance of coordination
of care across service providers was also highlighted as
the success of the model was dependent on capacity of
the service to engage in recruitment of participants and
TrueNTH activities, as well as the extent to which the
TrueNTH model was integrated with existing services
such as specialist prostate cancer nurses and multidisciplinary teams.
Implications for practice
Through this study, we have revealed new evidence to
guide future implementation of TrueNTH and similar
programmes. Specifically, findings from this study highlight that survivorship care interventions are relevant to
men at all stages of disease and treatment plan. Survivorship care interventions for men with prostate cancer and
their carers should therefore continue to incorporate principles that enable risk stratification, tailoring of services
to individual needs and optimisation rather than duplication of existing service capacity. We have established that
it is possible to provide access to a comprehensive model
of survivorship care, including a focus on improving
exercise and nutrition behaviours to promote health and
quality of life for men. The delivery of such interventions
by telehealth should continue where required, with additional efforts to upskill relevant care providers across a
broader range of settings. This requires ongoing use of
standardised needs assessment tools and regular service
capability assessments, as well as more formalised partnership agreements and protocols about the roles and
responsibilities of various service providers. Strategies
are also required to enable a greater focus on addressing
barriers associated with referral to and uptake of specific
services such as psychological support and sexual counselling. Moreover, survivorship interventions require care
coordination strategies that underpin the intervention to
manage the multiple service providers required to meet
the needs of men, including maintaining a single point of
contact, and use of shared assessment and care planning
tools.
This intervention incorporated a range of important
digital technologies to enable reach, uptake and effectiveness, including a web based shared care plan as well as
telehealth delivery. While the telehealth approaches were
widely accepted and resulted in broad reach, the digital
care planning platform was not as widely used outside of
the TrueNTH clinical team. While the platform was critical to sharing of information across the team, future platforms should draw on available evidence about effective
Yates P, et al. BMJ Open 2022;12:e049802. doi:10.1136/bmjopen-2021-049802
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Table 5 Programme enablers
Health system factors
Addressing service gaps I think you know that’s largely why this is in place because a lot of the men are in rural areas. So I
and extending service
think in that setting it’s very helpful. Pretty rare to get a psychiatrist or psychologist service on the
provision
phone. So in that sense like it’s sort of highly unique in Australia. (TNSP8)
There are definite gaps in service provision for men and their families with prostate cancer.
Particularly you know men who don't live in metropolitan cities. However, you know I even think that
men who do live in metropolitan cities don't always have access to great care either. You know you
can access care as an inpatient very easily but as soon as you become an outpatient it becomes
a very difficult thing to do. And so you know I think that TrueNTH fits really well into those gaps.
(TNSP1)
Once again a lot of our patients that we see I don’t think they are followed up with some of their
needs. They’re told they have cancer, they have surgery, and they’re shoved along, come back in
however many months for your next appointment, but there’s not any more assistance for them.
(Clinician4)
Providing specialised
services

In the public hospital I don’t think we’ve ever had anything for the patients like it before, so we’ve
never been able to follow up with their incontinence or unless they’ve come back through clinic. But
there’s never been anything like that or exercise they haven’t had these program available to them
before, so I think it’s just better options for people, better opportunities. (Clinician4)

Supporting carers

We pick up that there might be issues with the partner’s distress and grief. But often feel our hands
are tied as to what you can actually do for the partners. So I thought that was excellent support for
carers and partners that I felt that perhaps I couldn't offer as well. (Clinician6)

Intervention related factors
Needs-based approach I think that TrueNTH is able to tailor to that, we’re able to give very personalised, individualised care.
(TNSP1)
Each person wants a different level of support and I think too, the thing with this particular cohort is
some of them want quite a lot of support, others you’ll give them a defined meal plan and it makes
sense to them, they’ll do it from today until the rest of their life they’ll just keep doing it and don’t
need much so they’re very, they know themselves by this stage in life, very open and honest as a
group to communicate with so, you will generally find, as I said before if we get our first contact right
then we’re likely to have a reasonable impact. (TNSP6)
Telehealth based
approach

When I first started with TrueNTH I was a little bit sceptical about whether I could develop the same
rapport and provide the same support over, doing it as a telehealth service. But after working in the
clinic, I was there for eight years, so doing it in a physical sense and I'm now doing it as a telehealth
sense. There’s really no difference, I feel that I'm actually supporting these guys as well as I was
working face to face. (TNSP3)

Care coordination

There’s the importance of having a skilled and knowledgeable coordinator who knows how to
engage with both GPs and specialists is pretty key to this type of programme. I think that it needs to
have to be able to build that trust with the specialist that the person is not lost in any particular when
they’re getting some kind of shared care with the GP. (M1)
I think the TrueNTH staff were available if you needed help or if you wanted clarification and I think
they were diligent in their duties and support. (Clinician6)

Healthcare provider factors
Specialist expertise of
Skilled clinicians is what the program sits on, whether it’s the exercise physiology or xx being
TrueNTH team
dietician or the care coordinators, the commonality is our high levels of communication skills.
(TNSP4)
I think the TrueNTH program, it, to me it was more, it was more important to have somebody to talk
to at my level, more so than anything, you know? So, it was more helpful in that respect, to me….
like you guys were more helpful, and this is nothing against the Doctors or anything…. I think you
guys were more helpful, than the Doctors at the hospital. (Patient47)
I think all of the fields of expertise that were offered to me were really very well handled. They were
people who knew what they were talking about and they were all a great help. (Patient66)
M, Movember representative; TNSP, TrueNTH service provider.

technology enabled interventions to support its application in survivorship care, while maintaining flexibility to
respond to varying levels of technological literacy among
consumers and healthcare providers. The COVID-
19
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pandemic and subsequent pivoting to telehealth has
greatly advanced health professionals’ familiarity with
using digital technologies across Australia at the same
time that all age groups in the Australian community have
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Table 6 Programme barriers
Intervention related factors
Limitations of
The most difficult one is penile rehabilitation and the sexual rehabilitation and that’s really hard to do by
telehealth-based distance. (Clinician1)
approach
For example there might be a man who is quite advanced and for example if they’ve got … quite expansive
skeletal metastases I'm not usually comfortable with providing them a home based program, I don't want
them to exercise unsupervised. So I won’t provide that person with a program he can do on his own …. And
then I like toss-up between is he going to be better off just doing it unsupervised or should I be sticking to
no it’s not really safe for him to do it unsupervised? That can be tough in that situation. (TNSP5)
Insufficient
resources and
high caseload

Definitely needing to ensure dedicated, not just diary space or … but also physical space. I’ve always never
been a fan of sort of open plan offices. That’s an impediment I think to sort of free-flowing interactions
with patients…. So personal preference would be a room with dedicated access on that afternoon with
a camera. That would be good I think that would hopefully diminish the intrusion of other demands, that
requires widespread team sort of structure. (TNSP8)
Time restraints has been tough …. You go through phases where you are getting a large number of referrals
and each new referral is a significant amount of time on that individual. And when you’re getting a fair few
coming through at the same time it can be quite tough. Time and then when you’re also including all these
new referrals and you're trying to service as quickly as you can. If you’ve got a schedule to follow up you’re
organising at the same time. So things can fall behind, just even on track with time and that sort of thing has
been fairly difficult. (TNSP5)

Insufficient
integration with
existing services

It felt that we had to continually remind them. So even though this is a big teaching hospital with you know
very good history of …. And possibly because of that everybody’s time and focus is so you know you have
to keep reminding them that you’re there, that you’re present. And keep reminding them of the program.
(Clinician6)
Trying to gain momentum and support from nursing colleagues to deliver TrueNTH has been more difficult
than any other of the you know clinical fields. Just because there’s been a perceived threat to the work that
they’re already doing. (TNSP1)
I think the confused support from xx was a significant issue. We had mixed messages from their executives
to their nursing management, lack of support through the xx and their direct manager making it difficult to
have a working relationship and make the program work well in those settings where there was a prostate
cancer specialist nurse. So that was a problem the whole way through that was really difficult to navigate
and continues to be in that space. (M1)
In the times we attempted to get them engaged with local services, we found it took just as long to try to
get them to engage with local services and then more often than not they wouldn’t engage with the local
service. (TNSP6)

Healthcare provider factors
Quality of team
communication

I’d like it if there was better communication or integration between the clinicians, which cdmnet is not
doing. Because it feels like to me once the care coordinator refers to us then it’s, like I said before there’s no
feedback or overview. It feels like I can’t, when I feedback, I don’t know if it’s been accepted, I mean read,
unless I prompt them…. You’re supposed to go back to the GP, people are trained to go back to their GP
who coordinates everything. And if that’s the care coordinator then fine, but somehow the care coordinator
still has to extract themselves out of the systems once it’s done so they still have to go back to the GP or
the Specialist, and that bit I felt, that’s never been clear to me that that is being done nicely. (TNSP7)
X said she didn’t get a feedback from one of the case managers, that was, the guys was quite upset that he
hadn’t been contacted back by the case manager…. I think he needs a geriatrician review; I mean I did have
a look back at the notes to see what was done. (TNSP9)

Lower priority to
supportive care
issues

We are very, very busy clinics and sometimes you just don't have time with every prostate cancer patient
…. To actually sit down with the guys individually and have a good chat about the project was probably a
challenge for us…. But as I say just because of the sheer numbers we see and also we have kind of quite a
lot of registrars and junior staff who are changing over quite frequently, who probably weren’t aware of all…
all the staff of our unit weren’t aware of the program. So really I was the main one pushing for it and quite a
lot of the other staff they just needed constant reminders and things. (Clinician3)
Although now (supportive care) is more accepted and we want to do it, it’s still a little bit foreign to many of
the stakeholders that we would engage with. And particularly some medical specialists. You know they’re
very focussed on oncological care and so providing supportive care you know around lifestyle and mental
health and sexual dysfunction is not something that they would ordinarily put in their practice. (M2)
Patient related factors
Continued
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Table 6 Continued
Perceptions of
relevance of the
service

You get things like people don't have the time, a lot of, especially with this demographic, they don't see the
need for exercise. This is probably the main one is that feel, they basically don't see the need. One is that
they don't care for exercise and they don't see a reason to do it, I guess the benefits of exercise is still a
fairly new theory I guess, a new kind of treatment if you like. So a lot of the demographic that we look after
just don't see the benefit for it and don't see why there’s a need. (TNSP5)
Some guys didn't feel that they needed the service. Your typical you know rural, remote guy that doesn’t
like talking to people that sort of stuff. It was more the personality that was probably more the barrier than
anything else. (TNSP4)

Reluctance to
discuss needs

I don't want to be a grizzler.… He (TrueNTH care coordinator) rings up and I’ll tell him okay I’ll probably
say yeah all good I'm doing alright. So I'm just not quite sure how much TrueNTH is aware of the bladder
infections and the bowel complications and all that sort of stuff. I don't think that I’ve communicated that.
(Patient34)
Well it’s hard because not, blokes don't talk about what their problems are. Where I live here you know like
we’ve got a very close social group and that sort of thing and in the men there’s probably half a dozen that
have got similar problems to what I’ve got. But they’re not interested in doing anything about it. They don't
want to join a group or they just go to there have their tests and things done and they don't sort of worry
about it that much you know. (Patient51)
It’s not something I’ve used, not a lot of … I think there’s only been one of my guys that has wanted to use
the video, they’re all quite happy with the phone calls. (TNSP3)
We are very naïve with the … we really don't have a computer. I know it would be wonderful (video call) if I
could do it but I just, I go into a bit of a panic when there’s something new and I can't remember everything
I'm supposed to do. (Carer126)
For me personally, I like face to face. So it’s a bit hard for me to answer that because talking to somebody
on the phone is great but then you get off the phone and you know. So it’s a personal thing I guess really,
what each person reacts to and as I said I'm more a face to face person. (Carer80)

Reluctance/lack
of confidence
with technology

M, movember representative; TNSP, TrueNTH service provider.

embraced the use of digital technology into their day-
to-day social communication and acceptance of and familiarity with telehealth platforms is now greatly increased
from when this study was conducted. The success of the
TrueNTH model, therefore, provides great promise for
the future.
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Appendix 1. Numbers and proportions of men (n=142) using TrueNTH services by care pathway
TrueNTH services
Nutrition support
Exercise prescription
Psychosocial support
Sexual health
Continence support

Active surveillance Radiation
(n=16)
(n=6)
11 (69)
8 (50)
1 (6)
0 (0)
0 (0)

2 (33)
3 (50)
0 (0)
0 (0)
0 (0)

Surgery
(n=28)
15 (54)
14 (50)
3 (11)
4 (14)
2 (7)

Treatment
Advanced disease
completed (n=58)
(n=34)
31 (53)
42 (72)
8 (14)
6 (10)
6 (10)

21 (62)
22 (65)
3 (9)
0 (0)
1 (3)
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Appendix 2. Psychological distress and weekly leisure-time activity of men (n=142) by care
pathway

T0
T2
T4

Active
surveillance
(n=16)
n Mean (SD) n Mean (SD)
125 2.3 (3.3) 16 0.3 (1.0)
99 2.0 (3.2) 13 0.9 (1.6)
92 1.9 (3.1) 13 0.4 (1.1)

Change over time

79

19

p=0.14

Total weekly
leisure-time
activity score
(LSI)

T0
T2

119 31.1 (28.9) 16 36.4 (22.1)
93 39.5 (49.0) 13 37.2 (24.8)

4
3

58.8 (31.1) 24 34.6 (33.9) 50 28.9 (26.9)
79.7 (30.4) 16 30.7 (30.6) 39 50.4 (68.0)

25
22

24.2 (29.7)
22.6 (14.6)

T4

89 37.9 (35.4) 13 37.9 (19.2)

2

48.5 (20.5) 16 36.8 (35.7) 35 42.0 (44.8)

23

31.7 (27.2)

72

2

15

p=0.46

Time
point
Total GHQ
score

Change over time

All men
(n=142)

p=0.10

p=0.08

11

11

p=0.31

p=0.36

Radiation
(n=6)
n
4
3
2
2

Treatment
Advanced disease
completed
(n=34)
(n=58)
Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD)
0.8 (1.0) 24 2.8 (2.6) 52 2.1 (3.6)
29
3.5 (3.8)
0.0 (0.0) 18 2.1 (3.0) 42 1.9 (3.2)
23
3.1 (3.8)
0.0 (0.0) 16 1.4 (2.6) 37 2.1 (3.4)
22
2.8 (3.6)
p=0.50

p=0.47

Surgery
(n=28)

14

14

p=0.11

p=0.82

33

30

p=0.24

p=0.046

Notes: T0 = at enrolment, T2 = 6 months following enrolment, T4 = 12 months following enrolment.
Total GHQ mean score ranges from 0 to 12; a higher score indicates a greater severity of psychological distress.
A higher LSI scores means a higher level of leisure-time activity.
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Appendix 3. Proportion of men (n=142) reporting satisfactory experience of the health care system
during diagnosis and treatment
Domain

T0

Measures

n

T4

T2
n

n (%)

n

n (%)

n

test

93 (77)

96

71 (74)

86

68 (79)

69

p=0.52

68 (56)

96

57 (59)

89

57 (64)

54

p=0.63

n

test

Diagnosis
Completely understood the diagnosis 121
Information,
Were given written information
communication
about the diagnosis and it was easy 122
& education
to understand
Treatment
Were offered a written assessment
Coordination,
& care plan
integration of
Were given the name of a Clinical
care, continuity
Nurse Specialist for treatment
& transition
support
Adequate involvement in decisions
Respect for
about care & treatment
patients’
Patients’ views were taken into
preferences
account during treatment
The possible side effects of
Information,
treatments were explained in an
communication understandable way
Were given written information
& education
about the side effects of treatments

Change over
time

n (%)

121

33 (27)

97

33 (34)

89

35 (39)

37

p=0.047

121

54 (45)

95

50 (53)

90

47 (52)

55

p=0.21

122

69 (57)

97

61 (63)

90

53 (59)

72

p=0.10

119

61 (51)

94

57 (61)

90

47 (52)

57

p=0.19

121

65 (54)

97

60 (62)

90

51 (57)

71

p=0.40

118

76 (64)

93

54 (58)

87

46 (53)

54

p=0.63

Notes: T0 = at enrolment, T2 = 6 months following enrolment, T4 = 12 months following enrolment.
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